[2] In 2016, the FDA granted IND for clinical tests in combination with sorafenib for HCC.

"[3] Resminostat has undergone a phase I/II clinical trial for K-ras mutated advanced colorectal carcinoma.

[4] It has undergone a phase II clinical trial for relapsed or refractory Hodgkin's lymphoma.

[5] Resminostat restrains the phosphorylation of 4E-BP1 and p70S6k, indicating a disturbance with Akt signalling pathway.

[6] As with other HDAC inhibitors such as pracinostat, the inhibition of HDACs by resminostat results in an accumulation of highly acetylated histones, followed by an abduction of chromatin remodeling, inhibition of tumor suppressor genes transcription and cell division, and finally tumor cell apoptosis.